Ginkgo Bioworks Holdings, Inc. Annual Report - A Clearer Look for Investors

Welcome to your straightforward guide to Ginkgo Bioworks' performance over the past year, based on their latest SEC 10-K filing. We've distilled the key information, focusing on what truly matters for you as an investor, free from confusing jargon.

1. What does this company do and how did they perform this year?

Ginkgo Bioworks operates at the intersection of biology and technology, primarily through two main segments: Cell Engineering and Biosecurity. In Cell Engineering, they use their platform to design and program cells for various applications, from producing sustainable materials and ingredients to developing novel therapeutics. Their Biosecurity segment focuses on using biological expertise for pathogen detection and monitoring, a capability they significantly expanded during the recent pandemic.

This past year, Ginkgo strategically shifted its focus to streamline operations and pursue high-growth, high-margin opportunities. While overall revenue saw a modest decline, their strategic acquisitions and disposals show a clear intent to reshape their portfolio. They acquired AgBiome Inc. in April 2024 for approximately $170 million, gaining valuable technology rights in agricultural biologicals, and StrideBio in April 2023 for $175 million, strengthening their gene therapy capabilities. They also sold off Zymergen in October 2023 for $80 million and Altar SAS in 2024 for $15 million. These divestitures aimed at shedding non-core or underperforming assets, allowing Ginkgo to reallocate resources to more promising ventures and improve operational efficiency.

2. Financial performance - revenue, profit, growth metrics

Ginkgo Bioworks reported total revenue of $250 million for the fiscal year, a 15% decrease compared to the previous year. This 15% decline primarily stemmed from reduced Biosecurity revenue as pandemic-related testing subsided, though growth in their Cell Engineering segment partially offset it.

• Cell Engineering revenue grew by 10% to $180 million, due to increased program activity and milestone achievements.
• Biosecurity revenue decreased by 50% to $70 million, as anticipated with the wind-down of large-scale COVID-19 testing contracts.

The company reported a gross profit of $85 million, for a gross margin of 34%. Despite revenue challenges, Ginkgo continues to invest heavily in research and development, with R&D expenses totaling $450 million, and operating expenses reaching $700 million. As a result, Ginkgo reported a net loss of $850 million for the year. This loss reflects ongoing investments in platform development, strategic acquisitions, and non-cash items like stock-based compensation and impairment charges from divestitures. Management emphasizes future revenue growth from Cell Engineering programs as a key focus on the path to profitability.

3. Major wins and challenges this year

Major Wins:

• Strategic Cloud and AI Partnership with Google Cloud: This landmark partnership, extending through 2026, significantly accelerates Ginkgo's efforts. By integrating Google Cloud's advanced AI and machine learning capabilities with Ginkgo's biological data and automation, they aim to dramatically enhance their platform's design capabilities, reduce R&D timelines, and unlock new biological applications. This collaboration should drive innovation and attract new customers.
• Expansion of Cell Engineering Programs: Ginkgo successfully initiated 45 new Cell Engineering programs across various industries, including pharmaceuticals, agriculture, and sustainable materials, showing continued demand for their platform.
• Successful Integration of StrideBio: The StrideBio acquisition has already yielded promising results, expanding Ginkgo's gene therapy capabilities and attracting new biopharma partners.

Challenges/Changes:

• Revenue Contraction: The overall 15% revenue decline, primarily due to the Biosecurity segment, posed a significant challenge, necessitating strategic adjustments and a renewed focus on Cell Engineering growth.
• Restructuring and Employee Severance: The company incurred $35 million in employee severance costs as part of a broader restructuring initiative. While painful in the short term, this move aimed to streamline operations, reduce overhead, and align the workforce with strategic priorities for long-term efficiency gains.
• Portfolio Adjustments: The disposals of Zymergen and Altar SAS, while strategic, highlighted the need to shed underperforming or non-core assets. These divestitures can involve write-downs and impact short-term financial results.

4. Financial health - cash, debt, liquidity

Ginkgo Bioworks maintains a strong liquidity position, with $900 million in cash and cash equivalents at year-end. This includes significant investments in highly liquid assets like money market funds, corporate debt, and U.S. Treasury securities, providing a substantial runway for operations and strategic initiatives.

The company's total debt stands at $150 million, primarily convertible promissory notes due in 2026. With a current ratio of 3.5x, Ginkgo has ample capacity to cover its short-term obligations. This robust cash position and manageable debt give the company financial flexibility to fund ongoing R&D, potential future acquisitions, and navigate market uncertainties without immediate pressure to raise additional capital.

5. Key risks that could hurt the stock price

• Customer Concentration: Ginkgo relies heavily on a limited number of customers. One customer generated 28% of total revenue in the Cell Engineering segment, and another accounted for 20% of Biosecurity revenue. Losing or significantly reducing business from any of these key customers could materially impact Ginkgo's financial performance.
• Product/Sector Concentration: Approximately 40% of Ginkgo's Cell Engineering revenue comes from the Pharmaceutical and Biotechnology sector, and another 25% from Agriculture. Downturns, regulatory changes, or increased competition in these industries could disproportionately affect Ginkgo.
• Dilution from Warrants and Convertible Notes: The company has outstanding public and private warrants and convertible promissory notes. If exercised or converted into common stock, these could increase total shares outstanding by up to 15%, potentially diluting existing shares and impacting earnings per share.
• R&D Success and Commercialization: Ginkgo's business model relies heavily on successfully developing and commercializing new biological products and processes. R&D outcomes are inherently uncertain; failure to achieve technical milestones or secure commercial partners could hinder future revenue growth.
• Intellectual Property Protection: As a technology-driven company, Ginkgo's success depends on protecting its proprietary technology and trade secrets. Challenges to its intellectual property or inability to obtain new patents could weaken its competitive position.
• Regulatory Environment: The synthetic biology and biosecurity fields face evolving and complex regulatory frameworks. Adverse regulatory changes or increased scrutiny could impact Ginkgo's operations, product development, and market access.

6. Competitive positioning

Ginkgo Bioworks holds a strong competitive position in synthetic biology, thanks to its highly automated, data-driven platform and significant R&D investment. The Google Cloud and AI partnership is a game-changer, providing unparalleled access to advanced computing power and AI capabilities few competitors can match. This collaboration should accelerate their design-build-test-learn cycle, enabling faster development of novel biological solutions.

Their competitive advantages include:

• Scale and Automation: Ginkgo's foundries offer unparalleled scale and automation for biological experimentation.
• Data Advantage: A vast, growing proprietary dataset of biological insights fuels their AI-driven platform.
• Diverse Applications: Their platform's versatility allows them to address a wide range of industries, from pharma to agriculture and materials.
• Biosecurity Expertise: Their established Biosecurity segment provides a unique dual business model.

While the market is competitive with emerging biotech firms and established players, Ginkgo's strategic partnerships and platform approach aim to solidify its leadership.

7. Leadership or strategy changes

Current leadership drove significant strategic shifts this past year. The acquisitions of AgBiome and StrideBio, alongside the divestitures of Zymergen and Altar SAS, clearly signal a strategy focused on optimizing the portfolio for higher-value, core Cell Engineering opportunities and shedding non-strategic assets. This reflects a commitment to improving capital efficiency and accelerating the path to profitability.

The Google Cloud partnership is a cornerstone of their long-term strategy, emphasizing a future driven by AI and advanced computational biology. Financially, the company actively managed its capital structure through an At-the-Market (ATM) Program and a Sales Agreement with Allen Company LLC. Through these programs, Ginkgo successfully raised approximately $100 million in equity capital during the year, providing additional financial flexibility to fund operations and strategic growth initiatives without incurring significant debt. This proactive capital management demonstrates a focus on maintaining a strong balance sheet while pursuing growth.

8. Future outlook

Ginkgo's future outlook centers on using its enhanced Cell Engineering platform and the Google Cloud partnership to drive substantial growth and achieve profitability. The company aims to increase Cell Engineering program starts by 20-25% in the coming fiscal year, focusing on high-value applications in biopharma and sustainable industrial production.

The Google partnership should yield tangible results by 2025, with new AI-driven tools and capabilities accelerating customer program timelines and expanding Ginkgo's capabilities. Management has set a long-term goal of achieving positive adjusted EBITDA by 2026, driven by increased program revenue, improved operational efficiency from restructuring, and the scaling benefits of their platform. The ATM program provides a flexible mechanism to fund these ambitious goals.

9. Market trends or regulatory changes affecting them

Ginkgo Bioworks is well-positioned to capitalize on several key market trends:

• Growing Demand for Sustainable Production: Growing consumer and industrial demand for sustainable and bio-based products (e.g., alternative proteins, biodegradable materials) directly aligns with Ginkgo's Cell Engineering capabilities.
• Advancements in AI and Machine Learning: The rapid evolution of AI is a tailwind for Ginkgo, enhancing its platform's ability to design and optimize biological systems more efficiently.
• Increased Biosecurity Preparedness: Global awareness and investment in biosecurity infrastructure continue to grow, creating ongoing opportunities for Ginkgo's pathogen detection and monitoring services, though at a more stable level than during the pandemic peak.
• Favorable Regulatory Environment for Bio-manufacturing: Governments worldwide increasingly support bio-manufacturing initiatives through funding and policy, recognizing their potential for economic growth and environmental benefits.

However, the company also faces potential impacts from:

• Evolving Data Privacy Regulations: Stricter global data privacy laws could impact how Ginkgo collects and uses biological data.
• Biotech Patent Landscape: Changes in intellectual property law or increased patent litigation could affect their ability to protect innovations.

Overall, Ginkgo operates within a dynamic and generally favorable market and regulatory landscape, which, combined with its strategic initiatives, positions it for long-term growth.